Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.
Although a chew over in 2012 suggested a cancer deaden could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now conjecture they have been unable to duplicate those findings. The teams said their experimentation could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has unsmiling side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer pharmaceutical with punitive side effects," said study co-author Robert Vassar, a professor of chamber and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.

This way should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering clobber of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to manage refractory cutaneous T-cell lymphoma. Once approved, however, the narcotize also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to speedily reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the beginning study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the maturing of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the modern development research, admitted being skeptical about the initial findings.